Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 117-131, February 2009

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents

  • Simona Pisanti, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
  • ,
  • Anna Maria Malfitano, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
  • ,
  • Claudia Grimaldi, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
  • ,
  • Antonietta Santoro, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
  • ,
  • Patrizia Gazzerro, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
  • ,
  • Chiara Laezza, PhD (Doctor)

      Affiliations

    • Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy
  • ,
  • Maurizio Bifulco, MD (Professor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 089 969742; Fax: +39 089 969602.

Cannabinoids (the active components of Cannabis sativa) and their derivatives have received renewed interest in recent years due to their diverse pharmacological activities. In particular, cannabinoids offer potential applications as anti-tumour drugs, based on the ability of some members of this class of compounds to limit cell proliferation and to induce tumour-selective cell death. Although synthetic cannabinoids may have pro-tumour effects in vivo due to their immunosuppressive properties, predominantly inhibitory effects on tumour growth and migration, angiogenesis, metastasis, and also inflammation have been described. Emerging evidence suggests that agonists of cannabinoid receptors expressed by tumour cells may offer a novel strategy to treat cancer. In this chapter we review the more recent results generating interest in the field of cannabinoids and cancer, and provide novel suggestions for the development, exploration and use of cannabinoid agonists for cancer therapy, not only as palliative but also as curative drugs.

Keywords: cannabinoid agonists, CB receptors, cancer, inflammation, nausea, pain

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(09)00005-0

doi:10.1016/j.beem.2009.02.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 117-131, February 2009